{"filing":{"accession_number":"0001628280-26-045194","cik":"0001662579","ticker":"CCCC","company_name":"C4 Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"cccc-20260624.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/cccc-20260624.htm"},"events":[{"id":13522,"run_id":12018,"accession_number":"0001628280-26-045194","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from C4 Therapeutics' Annual Meeting of Stockholders held on June 24, 2026, covering four proposals: election of Class III directors (Hirsch, Fawell, Koppikar), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2020 Stock Option and Incentive Plan. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the hallmark of Item 5.07 shareholder vote results. This is material as it reflects stockholder approval of key governance and compensation matters.","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10682,"accession_number":"0001628280-26-045194","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from C4 Therapeutics' Annual Meeting of Stockholders held on June 24, 2026, covering four proposals: election of Class III directors (Hirsch, Fawell, Koppikar), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2020 Stock Option and Incentive Plan. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the hallmark of Item 5.07 shareholder vote results. This is material as it reflects stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:23:37.172406+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10682,"accession_number":"0001628280-26-045194","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from C4 Therapeutics' Annual Meeting of Stockholders held on June 24, 2026, covering four proposals: election of Class III directors (Hirsch, Fawell, Koppikar), advisory vote on named executive officer compensation, ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2020 Stock Option and Incentive Plan. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the hallmark of Item 5.07 shareholder vote results. This is material as it reflects stockholder approval of key governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T20:23:37.172406+00:00","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-06-24"}]}